BioSpace News Archive

WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a leader in digital health precision medicine today announced that they have received CE Mark approval for Bionov™, their professional-use clinical decision support software.

Invacare Corporation (Invacare) (NYSE:IVC) announced today the introduction of an innovative and pioneering active patient lift solution for the post-acute care setting into the U.S. market.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY), The Dental Solutions Company™, today announced that the Company will host an investor conference call and live webcast on Thursday, November 5, 2020 at 8:30 am ET and send out an earnings press release earlier that morning. A presentation related to the call will be available on www.dentsplysirona.com in the Investors section. Conference Call/Webcast Information Investors can access the webcast via a link

myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced the expansion of their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers. Under a 2019 agreement, myTo

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today confirmed receipt of a letter from PrimeStone Capital LLP (PrimeStone) to its Board of Directors and issued the following statement:

Walgreens Boots Alliance is delighted to announce that Co-Chief Operating Officer Ornella Barra was highly commended for her sustainability leadership at the Responsible Business Awards 2020, recognizing her innovation and her passionate commitment to promoting community health.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) for patients suffering from acute respiratory distress syndrome (ARDS) associated with COVID-19, which have been cleared for a Phase 1 clinical trial by the FDA. The study is a single arm, non-randomized P

Evotec SE announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash.

Kanaph Therapeutics, a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules, recently completed their Series B funding of 21M USD in South Korea.